{"blog": [], "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Abbott Laboratories", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Alere Inc", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Muddy Waters Research", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "St Jude Medical Inc", "name": "organizations", "rank": "5", "is_major": "Y"}, {"value": "White, Miles D", "name": "persons", "rank": "6", "is_major": "N"}, {"value": "Cyberattacks and Hackers", "name": "subject", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/08/27/business/dealbook/abbotts-no-good-very-bad-ma-week.html", "document_type": "article", "byline": {"person": [{"lastname": "PICKER", "firstname": "Leslie", "role": "reported", "organization": "", "rank": 1}], "original": "By LESLIE PICKER"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "700", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Abbott is acquiring Alere, which makes medical tests, and St. Jude Medical, which makes cardiovascular devices. The deals have been hampered by inquiries into sales practices and concerns over some devices being vulnerable to cyberattacks.", "pub_date": "2016-08-26T23:19:23+0000", "news_desk": "Business", "headline": {"print_headline": "2 Deals Turn Into 2 Headaches for Abbott Laboratories", "main": "Abbott\u2019s No Good, Very Bad M&amp;A Week"}, "print_page": "2", "snippet": "Abbott is acquiring Alere, which makes medical tests, and St. Jude Medical, which makes cardiovascular devices. The deals have been hampered by inquiries into sales practices and concerns over some devices being vulnerable to cyberattacks....", "_id": "57c0ce8395d0e021d7982e33", "slideshow_credits": null, "abstract": "Abbott Laboratories sees red flags go up on Wall Street over its pending acquisitions of Alere medical testing firm for $5.8 billion and St Jude Medical for $25 billion; analysts concerned over plan to take on amount of debt needed to finance two such large deals simultaneously say vulnerabilities of each target company would have been uncovered by proper due diligence."}